AXSM Q2 2021 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$31M

Net Income

-$32M

EPS (Diluted)

$-0.86

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$143M

Total Liabilities

$72M

Stockholders' Equity

$71M

Cash & Equivalents

$141M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$31M	-$18M	-73.5%
Net Income	-$32M	-$18M	-76.2%